Brooklyn Investment Group Has $58,000 Stock Holdings in Haleon plc (NYSE:HLN)

Brooklyn Investment Group increased its position in Haleon plc (NYSE:HLN) by 168.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,080 shares of the company’s stock after purchasing an additional 3,812 shares during the quarter. Brooklyn Investment Group’s holdings in Haleon were worth $58,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HLN. Merit Financial Group LLC acquired a new stake in shares of Haleon during the fourth quarter worth $152,000. Procyon Advisors LLC grew its position in shares of Haleon by 41.3% during the 4th quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock worth $2,196,000 after buying an additional 67,329 shares during the period. Ritholtz Wealth Management increased its stake in shares of Haleon by 128.1% in the 4th quarter. Ritholtz Wealth Management now owns 59,214 shares of the company’s stock valued at $565,000 after acquiring an additional 33,249 shares during the last quarter. Heritage Family Offices LLP raised its position in shares of Haleon by 7.4% in the 4th quarter. Heritage Family Offices LLP now owns 91,314 shares of the company’s stock valued at $871,000 after acquiring an additional 6,311 shares during the period. Finally, Park Avenue Securities LLC boosted its stake in Haleon by 41.5% during the 4th quarter. Park Avenue Securities LLC now owns 142,428 shares of the company’s stock worth $1,359,000 after acquiring an additional 41,807 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HLN. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Finally, UBS Group raised Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Trading Up 0.5 %

HLN stock opened at $9.24 on Monday. The stock has a market cap of $41.80 billion, a price-to-earnings ratio of 27.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.29. The company has a fifty day moving average price of $9.54 and a two-hundred day moving average price of $9.71. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.